BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.) for BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
H.R.7148 - Consolidated Appropriations Act, 2026
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINA INGRAM | — |
| DON LYSTER | — |
| PEDRO MONTENEGRO | — |
| LAURA WHITTON | — |
Health Issues HCR
S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 S. 3064 - the Relief of Chronic Disease Pain Act of 2026 S. 4189 - the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2026 H.R. 5467 - the Patient Access to Autoimmune Treatments Act S. 3105 / H.R. 8018 - the Increase Support for Life-saving Endocrine Transplantation Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to NIH/FDA funding Issues pertaining to screening and early detection
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINA INGRAM | — |
| DON LYSTER | — |
| PEDRO MONTENEGRO | — |
| LAURA WHITTON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.